International AIDS Vaccine Initiative
A003 Protocol - A Phase 1, randomized, blinded, dose-escalation study of rAAV1-PG9DP recombinant AAV vector coding for PG9 antibody in healthy male adults
Frances H. Priddy
Table for Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa
MOESM2 of Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes
Correlation between total and antigen-specific IgG responses and development of broadly neutralizing antibody responses.
Specificities mediating neutralization breadth and potency in the top 42 Protocol C neutralizers.
Evolution of broadly neutralizing antibody responses in plasma from Protocol C participants.
Correlation between clinical parameters and development of broadly neutralizing antibody responses.
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort
HIV incidence stratified by duration of time in study follow up, and (where data were available) by study year.
Enrollment and HIV incidence among at-risk volunteers enrolled for HIV prevention preparatory studies stratified by CRC and, where appropriate, sex.